RxDoctor Payments Data

Stefanie Marshall, DO

Obstetrics & Gynecology · Newark, DENPI 1184691156

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations.

$2,267in general payments, 2019–2025

Across 109 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$432
  • Caldera Medical, Inc$285
  • Astellas Pharma US Inc$201
  • Pfizer$162
  • Coopersurgical, Inc.$148
  • AbbVie$143
  • plus $895 from 20 others

What the payments were for

  • Food & beverage$2,25199%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,267 in reported general payments places this provider in the 80th percentile of 139 obstetrics & gynecology providers in Delaware.

See all obstetrics & gynecology providers in Delaware

Medicare billing

Part B allowed, 2024
$32,869
Medicare patients
302
Services billed
670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol61$6,327
Raloxifene Hcl17$1,763
ValacyclovirValacyclovir Hcl27$1,186
Risedronate Sodium13$948
Clobetasol Propionate18$374
Alendronate Sodium39$346

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →